SCHEMBL4178495

SCHEMBL4178495

COc1ccc(Nc2nnc(-c3cccnc3N(Cc3ccccc3)C3=COCO3)[nH]2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 2/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 5/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 2/20 0.34
KDR P35968 1/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
SHMT2 P34897 2/20 0.33
NPC1 O15118 1/20 0.33
CRHBP P24387 1/20 0.33
RAB9A P51151 1/20 0.33
CRHR2 Q13324 1/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4166085 0.95 KDM4E (0.39) ALDH1A1KDM4EHSD17B10MAPTUSP2
SCHEMBL4173778 0.88 KDM4E (0.36) ALDH1A1KDM4EMAPTNPSR1POLB
SCHEMBL4175509 0.88 ALDH1A1 (0.44) ALDH1A1KDM4EHSD17B10MAPTUSP2
SCHEMBL4173168 0.88 MEN1 (0.37) ALDH1A1MAPTKDRPOLBHTT
SCHEMBL4180570 0.83 KDM4E (0.38) ALDH1A1KDM4EHSD17B10MAPTUSP2
SCHEMBL4179206 0.76 KDM4E (0.35) ALDH1A1KDM4EMAPTLMNATSHR
SCHEMBL4173348 0.76 MEN1 (0.36) ALDH1A1MAPTNPSR1KDRPOLB
SCHEMBL4176947 0.75 TUBB4A (0.35) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4175506 0.75 ALDH1A1 (0.39) ALDH1A1KDM4EHSD17B10MAPTUSP2
SCHEMBL4181133 0.73 TUBB4A (0.44) ALDH1A1MAPTPOLBHTTTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
WO-2005004818-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL ALDH1A1 535/4885KDM4E 2144/4885HSD17B10 1779/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL ALDH1A1 535/4885KDM4E 2144/4885HSD17B10 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.